Xenon (XENE) Receives a Buy from Needham

Needham analyst Serge Belanger maintained a Buy rating on Xenon (XENEResearch Report) today and set a price target of $25.00. The company’s shares closed last Wednesday at $16.02.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of 0.0% and a 41.2% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.

Xenon has an analyst consensus of Strong Buy, with a price target consensus of $27.00, representing a 68.5% upside. In a report issued on September 9, Leerink Partners also maintained a Buy rating on the stock with a $28.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.94 and a one-year low of $9.32. Currently, Xenon has an average volume of 182.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.